Chapter title |
Recombinant human GM-CSF in small cell lung cancer: a phase I/II study.
|
---|---|
Chapter number | 17 |
Book title |
Supportive Care in Cancer Patients II
|
Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 1991
|
DOI | 10.1007/978-3-642-84138-5_17 |
Pubmed ID | |
Book ISBNs |
978-3-64-284140-8, 978-3-64-284138-5
|
Authors |
Anderson, H, Gurney, H, Thatcher, N, Swindell, R, Scarffe, J H, Weiner, J, Anderson, H., Gurney, H., Thatcher, N., Swindell, R., Scarffe, J. H., Weiner, J. |
Abstract |
Seventeen patients with small cell lung cancer were entered into a dose ranging phase I-II study using rhGM-CSF (Glaxo). In the phase I study patients received 50, 150, 300 or 500 micrograms/m2 GM-CSF for 10 days by daily subcutaneous injection. Full blood counts were performed thrice weekly. After 4 days off all therapy patients then received chemotherapy with doxorubicin 50 mg/m2 i.v. bolus, day 1, ifosfamide 5 g/m2 with mesna 5 g/m2 over 24 h by continuous infusion followed by mesna 3 g/m2, and etoposide 120 mg/m2 i.v. on days 1-3. A total of six courses of chemotherapy were given. In the phase II study patients received the same dose of GM-CSF as in the phase I. GM-CSF was given 24 h after the last dose of chemotherapy for 14 days. Full blood counts were checked thrice weekly and the incidence of infections noted. Patients were randomised to receive GM-CSF with either odd or even courses of chemotherapy. The leucocyte count rose from a mean of 8.7 to 21.6 x 10(9)/l at the 50 micrograms/m2 GM-CSF dosage and from 11.4 to 39.4 x 10(9)/l at the 500 micrograms/m2 dosage during the phase I study. Phase I toxicity was: bone pain in 65% of patients, rash in 47%, fever in 24%, lethargy in 12% and diarrhoea in 12%. In the phase II study the duration of neutropenia was less during the chemotherapy courses with GM-CSF (p = 0.04) but the number of infections was similar.(ABSTRACT TRUNCATED AT 250 WORDS) |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 5 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 2 | 40% |
Student > Ph. D. Student | 1 | 20% |
Lecturer | 1 | 20% |
Professor > Associate Professor | 1 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 60% |
Sports and Recreations | 1 | 20% |
Unknown | 1 | 20% |